E2F1 and prostate adenocarcinoma: We analyzed E2F1 profiling using two public databases (Trento/Cornell/Broad 2016 and the TCGA prostate adenocarcinoma, provisional), and found that E2F1 is either amplified or elevated in a significant portion of patients [39,40,41].